Patents by Inventor Fude Huang

Fude Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HALOGENATED PHENYLARSINE OXIDE COMPOUND AND APPLICATION THEREOF
    Publication number: 20240391942
    Abstract: A fluorinated phenylarsine oxide or a pharmaceutically acceptable salt thereof, relating to a pharmaceutical composition containing a pharmaceutically acceptable carrier and a fluorinated phenylarsine oxide. The fluorinated phenylarsine oxide can be used for treating and preventing cancer and related diseases.
    Type: Application
    Filed: September 30, 2022
    Publication date: November 28, 2024
    Inventors: Fude HUANG, Feng HONG, Wenan WANG, Jiangang ZHANG, Yuyu XIE, Hao ZHANG, Changping JIAO, Luxiang CAO, Linan ZHENG, Changde HUANG, Lijuan HOU, Liping MA, Jinlian LU, Li FANG, Peiyun AN
  • APPLICATIONS OF P14K INHIBITOR IN INTRACELLULAR PROTEIN MISFOLDING-RELATED DISEASES AND LYSOSOMAL STORAGE DISEASES
    Publication number: 20240261250
    Abstract: Provided are uses of a PI4KIII? specific inhibitor in preventing or treating intracellular protein misfolding-related diseases, also provided are uses of the PI4KIII? specific inhibitor in preventing or treating lysosomal storage diseases.
    Type: Application
    Filed: March 31, 2021
    Publication date: August 8, 2024
    Inventors: Fude Huang, Wenan Wang, Feng Hong, Linan Zheng, Changping Jiao, Luxiang Cao, Yuyu Xie
  • Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease
    Publication number: 20240173287
    Abstract: The use of a genetic method to down-regulate RBO/EFR3/EFR3A/EFR3B proteins, TTC7 protein or PI4KIII? enzyme protein which interacts with RBO/EFR3/EFR3A/EFR3B proteins and TTC7 protein, or the use of a drug to inhibit PI4KIII? protein kinase activity reduces the accumulation of A?42 within neurons and age-dependent synaptic transmission failure and other obstacles in a fruit fly AD model, and obtains an effect of improving the learning and memory abilities of AD model mice. Provided is a method for using an RBO/EFR3/EFR3A/EFR3B inhibitor, a TTC7 inhibitor and a PI4KIII? inhibitor to treat Alzheimer's disease. Also provided is a method for screening a drug treating Alzheimer's disease by whether A? secretion by nerve cells is promoted or not.
    Type: Application
    Filed: September 18, 2023
    Publication date: May 30, 2024
    Inventors: Fude Huang, Xiao Zhang, Wenan Wang, Le Zhang, Lixiang Jiang, Tong Zhu, Haiyan Liu, Yudong Zhou, Yang He, Wanguo Wei
  • DEUTERATED OXOPHENYLARSINE COMPOUND AND USE THEREOF
    Publication number: 20240050395
    Abstract: Disclosed are a deuterated oxophenylarsine, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing a pharmaceutically acceptable carrier and the deuterated oxophenylarsine. The deuterated oxophenylarsine can be used for treating and preventing cancers and related diseases.
    Type: Application
    Filed: March 31, 2021
    Publication date: February 15, 2024
    Inventors: Fude Huang, Wenan Wang, Feng Hong, Wanguo Wei, Jiangang Zhang, Changping Jiao, Luxiang Cao
  • Application of PI4KIIIA protein and related membrane protein complex in treating alzheimer's disease
    Patent number: 11766420
    Abstract: The use of a genetic method to down-regulate RBO/EFR3/EFR3A/EFR3B proteins, TTC7 protein or PI4KIII? enzyme protein which interacts with RBO/EFR3/EFR3A/EFR3B proteins and TTC7 protein, or the use of a drug to inhibit PI4KIII? protein kinase activity reduces the accumulation of A?42 within neurons and age-dependent synaptic transmission failure and other obstacles in a fruit fly AD model, and obtains an effect of improving the learning and memory abilities of AD model mice. Provided is a method for using an RBO/EFR3/EFR3A/EFR3B inhibitor, a TTC7 inhibitor and a PI4KIII? inhibitor to treat Alzheimer's disease. Also provided is a method for screening a drug treating Alzheimer's disease by whether A? secretion by nerve cells is promoted or not.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: September 26, 2023
    Assignee: JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO. LTD.
    Inventors: Fude Huang, Xiao Zhang, Wenan Wang, Le Zhang, Lixiang Jiang, Tong Zhu, Haiyan Liu, Yudong Zhou, Yang He, Wanguo Wei
  • MICROMOLECULE PI4KIIIalpha INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20230115711
    Abstract: Disclosed is a pharmaceutical composition comprising a micromolecule PI4KIII? inhibitor and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises a lipid. Also disclosed are a method for preparing the pharmaceutical composition, and a method for treating PI4KIII?-related diseases by using the pharmaceutical composition.
    Type: Application
    Filed: July 6, 2020
    Publication date: April 13, 2023
    Inventors: Fude HUANG, Feng WANG, Shu YANG, Changping JIAO, Xiaojun ZHOU
  • METHOD FOR TREATING MOOD DISORDERS
    Publication number: 20220362203
    Abstract: Provided are an inhibitor of PI4KIII?/FAM126/TTC7 complex and a method that uses the inhibitor to prevent or treat mood disorders.
    Type: Application
    Filed: September 27, 2020
    Publication date: November 17, 2022
    Inventors: Fude HUANG, Wen'an WANG, Changping JIAO, Changde HUANG, Tide HUANG
  • Method for screening drug and therapeutic targets used for treating Alzheimer's disease
    Patent number: 11236378
    Abstract: Disclosed is the use of genetic means or a related inhibitor to inhibit and down-regulate the amount of PI4KIII? protein, RBO/EFR3/EFR3A/EFR3B membrane proteins, TTC7 protein and membrane protein complexes formed by said proteins, or related enzyme activity to promote A? secretion by neuronal cells, reduce A? accumulation within neurons, and thereby reduce AD model fruit fly and mouse nerve dysfunction.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: February 1, 2022
    Assignee: Jiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd.
    Inventors: Fude Huang, Xiao Zhang, Wenan Wang, Haiyan Liu
  • Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease
    Publication number: 20190314321
    Abstract: The use of a genetic method to down-regulate RBO/EFR3/EFR3A/EFR3B proteins, TTC7 protein or PI4KIII? enzyme protein which interacts with RBO/EFR3/EFR3A/EFR3B proteins and TTC7 protein, or the use of a drug to inhibit PI4KIII? protein kinase activity reduces the accumulation of A?42 within neurons and age-dependent synaptic transmission failure and other obstacles in a fruit fly AD model, and obtains an effect of improving the learning and memory abilities of AD model mice. Provided is a method for using an RBO/EFR3/EFR3A/EFR3B inhibitor, a TTC7 inhibitor and a PI4KIII? inhibitor to treat Alzheimer's disease. Also provided is a method for screening a drug treating Alzheimer's disease by whether A? secretion by nerve cells is promoted or not.
    Type: Application
    Filed: May 3, 2016
    Publication date: October 17, 2019
    Inventors: Fude Huang, Xiao Zhang, Wenan Wang, Le Zhang, Lixiang Jiang, Tong Zhu, Haiyan Liu, Yudong Zhou, Yang He, Wanguo Wei
  • Method For Screening Drug And Therapeutic Targets Used For Treating Alzheimer's Disease
    Publication number: 20190211371
    Abstract: Disclosed is the use of genetic means or a related inhibitor to inhibit and down-regulate the amount of PI4KIII? protein, RBO/EFR3/EFR3A/EFR3B membrane proteins, TTC7 protein and membrane protein complexes formed by said proteins, or related enzyme activity to promote A? secretion by neuronal cells, reduce A? accumulation within neurons, and thereby reduce AD model fruit fly and mouse nerve dysfunction.
    Type: Application
    Filed: April 30, 2015
    Publication date: July 11, 2019
    Inventors: Fude Huang, Xiao Zhang, Wenan Wang, Haiyan Liu